| 2.13 -0.09 (-4.05%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.04  |
1-year : | 3.5 |
| Resists | First : | 2.61 |
Second : | 3 |
| Pivot price | 2.58 |
|||
| Supports | First : | 1.98 |
Second : | 1.64 |
| MAs | MA(5) : | 2.4 |
MA(20) : | 2.64 |
| MA(100) : | 1.7 |
MA(250) : | 1.52 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 3.9 |
D(3) : | 13.3 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 3.78 | Low : | 1.08 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RGLS ] has closed below the lower bollinger band by 6.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ RGLS ] is to continue within current trading range. It is unclear right now based on current values. 62% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.33 - 2.35 | 2.35 - 2.36 |
| Low: | 2.05 - 2.07 | 2.07 - 2.09 |
| Close: | 2.1 - 2.14 | 2.14 - 2.17 |
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Mon, 15 Apr 2024
Do Options Traders Know Something About Regulus Therapeutics (RGLS) Stock We Don't? - Yahoo Movies UK
Wed, 10 Apr 2024
Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD (NASDAQ:RGLS) - Seeking Alpha
Sat, 23 Mar 2024
Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements - GuruFocus.com
Thu, 21 Mar 2024
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates - PR Newswire
Thu, 14 Mar 2024
Should You Buy Regulus Therapeutics Inc (RGLS) Stock Thursday Morning? - InvestorsObserver
Wed, 13 Mar 2024
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 43.6 (%) |
| Shares Short | 5,420 (K) |
| Shares Short P.Month | 55 (K) |
| EPS | -1.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.04 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -50.3 % |
| Return on Equity (ttm) | -110.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -1.35 |
| PEG Ratio | -0.2 |
| Price to Book value | 2.02 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|